OTCBB:SNGXD - (SNGXD) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New (SNGXD) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNGXD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNGXD

Average Price Target: $0.00
This price target is based on 0 analysts offering 12 month price targets for (SNGXD) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in (SNGXD). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2017Maxim GroupBoost Price TargetBuy$4.00 ➝ $5.00
7/17/2017HC WainwrightInitiated CoverageBuy$11.00
6/19/2017Maxim GroupReiterated RatingBuy$4.00
5/12/2017Maxim GroupReiterated RatingBuy$35.00
5/4/2017Maxim GroupReiterated RatingBuy$4.00
3/27/2017Maxim GroupReiterated RatingBuy$4.00
3/11/2017Maxim GroupSet Price TargetBuy$4.00
12/19/2016Maxim GroupBoost Price TargetBuy$3.00 ➝ $4.00
(Data available from 6/21/2016 forward)

(SNGXD)

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

6,763 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (SNGXD)?

The following sell-side analysts have issued stock ratings on (SNGXD) in the last year:
View the latest analyst ratings for SNGXD.

What is the current price target for (SNGXD)?

0 Wall Street analysts have set twelve-month price targets for (SNGXD) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (SNGXD) in the next year.
View the latest price targets for SNGXD.

What is the current consensus analyst rating for (SNGXD)?

(SNGXD) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SNGXD.

How do I contact (SNGXD)'s investor relations team?

(SNGXD)'s physical mailing address is 29 Emmons Dr Ste C10, PRINCETON, NJ 08540-5919, United States. The company's listed phone number is +1-609-5388200. The official website for (SNGXD) is www.soligenix.com.